|
業務類別
|
-- |
|
業務概覽
|
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for people with cancer. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. It is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma. |
| 公司地址
| 1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138 |
| 電話號碼
| +1 617 453-1000 |
| 傳真號碼
| +1 617 453-1001 |
| 公司網頁
| https://www.infi.com |
| 員工數量
| 17 |
| Mr. Seth A. Tasker, J.D. |
Chief Executive Officer |
-- |
01/09/2023 |
|
|
| Dr. Anthony B. Evnin,PhD |
Independent Director |
28/03/2023 |
| Ms. Adelene Q. Perkins |
Chairman of the Board |
01/09/2023 |
| Mr. David William Beier, J.D. |
Independent Director |
28/03/2023 |
| Mr. Norman C. Selby |
Lead Independent Director |
28/03/2023 |
| Dr. Richard B. Gaynor, M.D. |
Independent Director |
28/03/2023 |
|
|
|
|
